Connect your AI

Pershing Square PS Accrued Litigation

Accrued Litigation at other companies

LivaNovaLIVN

$9.64M-27.0%

LQD

Liquidia CorporationLQDA

$8.55M+13.4%

Indivior Pharmaceuticals, Inc. INDV

$41M-86.2%

JAN

Janus Living JAN

$660K+1,220%

Amneal Pharmaceuticals, Inc.AMRX

$70.02M-4.1%

Service Corporation InternationalSCI

$19.05M+38.1%

Other financials

Income statement

Revenue$57.5M+9.9%

Operating income$5.1M-51.2%

Net income-$147.6M-848%

Balance sheet

Cash & equivalents$46.8M-95.0%

Total debt$91.2M—

Total equity$884.5M-7.0%

Total assets$990.5M—

Cash flow

Operating cash flow$87.9M+35.1%

Valuation

Market cap$13.33B—

Enterprise value$13.38B—

Returns & leverage

Debt / equity0.1×—

Where this comes from

Reported directly by Pershing Square in its filing.

Tagged under the XBRL concept us-gaap:LitigationReserve.

The official record: Pershing Square ’s 10-Q, filed June 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pershing Square 's accrued litigation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Pershing Square 's accrued litigation?: Pershing Square (PS) reported accrued litigation of $0 in Q1 2026.